HANXBIO-B repurchases 16,000 H-shares; treasury stock rises to 1.71 million

Bulletin Express07-02 19:59

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back in a Next Day Disclosure Return filed on 2 July 2026 with the Hong Kong Stock Exchange.

The company repurchased 16,000 H-shares on 2 July 2026 via on-market transactions, representing 0.012% of its issued share capital (excluding treasury shares) as of 30 June 2026. The shares were bought at prices ranging between HKD 27.96 and HKD 28.68, with a volume-weighted average of HKD 28.50, for a total consideration of HKD 0.46 million.

Post-transaction, the number of issued shares (excluding treasury shares) declined from 134.52 million to 134.51 million. Treasury shares increased correspondingly from 1.70 million to 1.71 million, while total issued shares remained unchanged at 136.22 million.

The buy-back forms part of the repurchase mandate approved on 24 June 2026, which authorises the company to repurchase up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 189,600 shares, equivalent to 0.14% of the issued shares outstanding on the mandate date. Under Hong Kong listing rules, HANXBIO-B is subject to a moratorium on new share issues or treasury share disposals until 1 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199259891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199259891","market":"hk","top_or_hot":-1,"title":"HANXBIO-B repurchases 16,000 H-shares; treasury stock rises to 1.71 million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back in a Next Day Disclosure Return filed on 2 July 2026 with the Hong Kong Stock Exchange.</p>\n<p>The company repurchased 16,000 H-shares on 2 July 2026 via on-market transactions, representing 0.012% of its issued share capital (excluding treasury shares) as of 30 June 2026. The shares were bought at prices ranging between HKD 27.96 and HKD 28.68, with a volume-weighted average of HKD 28.50, for a total consideration of HKD 0.46 million.</p>\n<p>Post-transaction, the number of issued shares (excluding treasury shares) declined from 134.52 million to 134.51 million. Treasury shares increased correspondingly from 1.70 million to 1.71 million, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The buy-back forms part of the repurchase mandate approved on 24 June 2026, which authorises the company to repurchase up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 189,600 shares, equivalent to 0.14% of the issued shares outstanding on the mandate date. Under Hong Kong listing rules, HANXBIO-B is subject to a moratorium on new share issues or treasury share disposals until 1 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 16,000 H-shares; treasury stock rises to 1.71 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 16,000 H-shares; treasury stock rises to 1.71 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 19:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back in a Next Day Disclosure Return filed on 2 July 2026 with the Hong Kong Stock Exchange.</p>\n<p>The company repurchased 16,000 H-shares on 2 July 2026 via on-market transactions, representing 0.012% of its issued share capital (excluding treasury shares) as of 30 June 2026. The shares were bought at prices ranging between HKD 27.96 and HKD 28.68, with a volume-weighted average of HKD 28.50, for a total consideration of HKD 0.46 million.</p>\n<p>Post-transaction, the number of issued shares (excluding treasury shares) declined from 134.52 million to 134.51 million. Treasury shares increased correspondingly from 1.70 million to 1.71 million, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The buy-back forms part of the repurchase mandate approved on 24 June 2026, which authorises the company to repurchase up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 189,600 shares, equivalent to 0.14% of the issued shares outstanding on the mandate date. Under Hong Kong listing rules, HANXBIO-B is subject to a moratorium on new share issues or treasury share disposals until 1 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1199259891","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199259891","pubTimestamp":1782993592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back in a Next Day Disclosure Return filed on 2 July 2026 with the Hong Kong Stock Exchange. The company repurchased 16,000...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"瀚讯生物-B回购1.6万股H股；库存股升至171万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back in a Next Day Disclosure Return filed on 2 July 2026 with the Hong Kong Stock Exchange.\nThe company repurchased 16,000 H-shares on 2 July 2026 via on-market transactions, representing 0.012% of its issued share capital (excluding treasury shares) as of 30 June 2026. The shares were bought at prices ranging between HKD 27.96 and HKD 28.68, with a volume-weighted average of HKD 28.50, for a total consideration of HKD 0.46 million.\nPost-transaction, the number of issued shares (excluding treasury shares) declined from 134.52 million to 134.51 million. Treasury shares increased correspondingly from 1.70 million to 1.71 million, while total issued shares remained unchanged at 136.22 million.\nThe buy-back forms part of the repurchase mandate approved on 24 June 2026, which authorises the company to repurchase up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 189,600 shares, equivalent to 0.14% of the issued shares outstanding on the mandate date. Under Hong Kong listing rules, HANXBIO-B is subject to a moratorium on new share issues or treasury share disposals until 1 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199259891","isCrawlerRequest":true}